- Home
- BDRX vs CVKD Comparison
BDRX vs CVKD Comparison
Compare BDRX & CVKD Stocks: Price Trends, ML Decisions, Charts, Trends, Technical Analysis and more.
- Machine Learning Prediction
- ML Decision
- BDRX
- CVKD
- Stock Information
- Founded
- BDRX 2000
- CVKD 2022
- Country
- BDRX United Kingdom
- CVKD United States
- Employees
- BDRX N/A
- CVKD N/A
- Industry
- BDRX Biotechnology: Pharmaceutical Preparations
- CVKD Medicinal Chemicals and Botanical Products
- Sector
- BDRX Health Care
- CVKD Health Care
- Exchange
- BDRX Nasdaq
- CVKD Nasdaq
- Market Cap
- BDRX 5.8M
- CVKD 29.5M
- IPO Year
- BDRX N/A
- CVKD 2023
- Fundamental
- Price
- BDRX $0.86
- CVKD $12.80
- Analyst Decision
- BDRX
- CVKD Strong Buy
- Analyst Count
- BDRX 0
- CVKD 1
- Target Price
- BDRX N/A
- CVKD $32.00
- AVG Volume (30 Days)
- BDRX 3.1M
- CVKD 32.3K
- Earning Date
- BDRX 04-11-2025
- CVKD 08-06-2025
- Dividend Yield
- BDRX N/A
- CVKD N/A
- EPS Growth
- BDRX N/A
- CVKD N/A
- EPS
- BDRX N/A
- CVKD N/A
- Revenue
- BDRX N/A
- CVKD N/A
- Revenue This Year
- BDRX N/A
- CVKD N/A
- Revenue Next Year
- BDRX N/A
- CVKD N/A
- P/E Ratio
- BDRX N/A
- CVKD N/A
- Revenue Growth
- BDRX N/A
- CVKD N/A
- 52 Week Low
- BDRX $0.78
- CVKD $5.70
- 52 Week High
- BDRX $41.50
- CVKD $22.90
- Technical
- Relative Strength Index (RSI)
- BDRX 36.41
- CVKD 49.60
- Support Level
- BDRX $0.83
- CVKD $11.00
- Resistance Level
- BDRX $0.90
- CVKD $13.71
- Average True Range (ATR)
- BDRX 0.11
- CVKD 1.14
- MACD
- BDRX 0.00
- CVKD 0.10
- Stochastic Oscillator
- BDRX 14.57
- CVKD 63.54
About BDRX Biodexa Pharmaceuticals plc
Biodexa Pharmaceuticals PLC is a clinical-stage biopharmaceutical company focused on developing a pipeline of products to treat diseases that have unmet medical needs. These include familial adenomatous polyposis (FAP), non-muscle invasive bladder cancer (NMIBC), type 1 diabetes (T1D), and rare or orphan brain cancers.
About CVKD Cadrenal Therapeutics Inc.
Cadrenal Therapeutics Inc is developing tecarfarin, its drug candidate, for unmet needs in anticoagulation therapy. Tecarfarin is a late-stage novel oral and reversible anticoagulant (blood thinner) designed to prevent heart attacks, strokes, and deaths due to blood clots in patients with rare cardiovascular conditions requiring chronic anticoagulation.